Last reviewed · How we verify
NCT07518940: ENERGIA
ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia
NA trial testing Participants will take part in a 12-week exercise program that includes aerobic and resistance training, tailored to their individual fitness level and clinical condition. in Myeloproliferative Disease in 25 participants. Not yet recruiting.
1 September 2027
Quick facts
| Lead sponsor | Carmen Fava |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 1 August 2026 |
| Primary completion | 1 September 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Participants will take part in a 12-week exercise program that includes aerobic and resistance training, tailored to their individual fitness level and clinical condition.
Conditions studied
- Myeloproliferative Disease — all drugs for Myeloproliferative Disease →
- Polycythemia Vera — all drugs for Polycythemia Vera →
- Thrombocythemia Essential — all drugs for Thrombocythemia Essential →
- Myelofibrosis, Primary — all drugs for Myelofibrosis, Primary →
Sponsor
Carmen Fava
Who can join
18 and older, any sex, with Myeloproliferative Disease or Polycythemia Vera. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates whether a personalized, supervised exercise program can improve fatigue and physical function in patients with myeloproliferative neoplasms (MPN) and chronic myeloid leukemia (CML). Although many patients achieve good disease control with modern therapies, they often experience persistent symptoms such as fatigue that significantly affect daily life. Participants will take part in a 12-week exercise program that includes aerobic and resistance training, tailored to their individual fitness level and clinical condition. The program consists of two supervised sessions per week, along with additional home-based aerobic activity. Before and after the program, participants will undergo comprehensive assessments, including cardiopulmonary exercise testing, physical function tests, questionnaires on fatigue and quality of life, and blood sample collection. The study aims to determine whether this type of exercise program is feasible and safe, and whether it can reduce fatigue and improve physical capacity, quality of life, and biological markers related to inflammation and metabolism. Participants will also be followed after the intervention to evaluate whether the benefits are maintained over time.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07518940
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myeloproliferative Disease
Currently open trials in the same condition.
- NCT07204392 — Unveiling the Germline Predisposition to Myeloproliferative Neoplasms · recruiting
- NCT07204366 — Autoantibodies Against Type I Interferon in Patients Affected With Ph-negative Myeloproliferative Neoplasms (MPN-IFN Stu · active not recruiting
Other Carmen Fava trials
Trials by the same sponsor.
- NCT06724536 — Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07518940 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Carmen Fava
- Last refreshed: 9 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07518940.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing